MX2017016719A - Composición farmacéutica combinada para la prevención de la formación de productos finales de la glicación avanzada. - Google Patents

Composición farmacéutica combinada para la prevención de la formación de productos finales de la glicación avanzada.

Info

Publication number
MX2017016719A
MX2017016719A MX2017016719A MX2017016719A MX2017016719A MX 2017016719 A MX2017016719 A MX 2017016719A MX 2017016719 A MX2017016719 A MX 2017016719A MX 2017016719 A MX2017016719 A MX 2017016719A MX 2017016719 A MX2017016719 A MX 2017016719A
Authority
MX
Mexico
Prior art keywords
pharmaceutical composition
formation
prevent
advanced glycation
carboxy
Prior art date
Application number
MX2017016719A
Other languages
English (en)
Inventor
Raúl MEIXUEIRO MONTES DE OCA Juan
Original Assignee
Alepharma Soc Anonima Promotora De Inversion De Capital Variable
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alepharma Soc Anonima Promotora De Inversion De Capital Variable filed Critical Alepharma Soc Anonima Promotora De Inversion De Capital Variable
Priority to MX2017016719A priority Critical patent/MX2017016719A/es
Priority to US16/108,239 priority patent/US11406636B2/en
Publication of MX2017016719A publication Critical patent/MX2017016719A/es
Priority to US17/818,058 priority patent/US20220370449A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A61K31/51—Thiamines, e.g. vitamin B1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4415—Pyridoxine, i.e. Vitamin B6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin

Abstract

La presente invención se refiere a una composición farmacéutica, fisicoquímicamente estable, en una unidad de dosis caracterizada porque comprende cantidades efectivas de los principios activos tiamina (Vitamina B1), piridoxina (Vitamina B6), un fiavonoide como la quercetina y un polifenol como la curcumina, o sus sales farmacéuticamente aceptables en combinación con excipientes farmacéuticamente aceptables, para la prevención de la formación y/o atrapamiento de los productos finales de la glicación avanzada (glioxal, metilglioxal, N-carboxi-metil-Iisina, N-carboxi-etil-lisina, pirralina, pentosidina, dímero de lisina, etc), que puede ser empleada en el tratamiento y/o prevención de las complicaciones de la diabetes mellitus (neuropatía, nefropatía y retinopatía diabética). La composición farmacéutica de la invención se presenta en forma oral, preferentemente en cápsula, tableta o sobre para administración oral.
MX2017016719A 2017-12-19 2017-12-19 Composición farmacéutica combinada para la prevención de la formación de productos finales de la glicación avanzada. MX2017016719A (es)

Priority Applications (3)

Application Number Priority Date Filing Date Title
MX2017016719A MX2017016719A (es) 2017-12-19 2017-12-19 Composición farmacéutica combinada para la prevención de la formación de productos finales de la glicación avanzada.
US16/108,239 US11406636B2 (en) 2017-12-19 2018-08-22 Combined pharmaceutical composition
US17/818,058 US20220370449A1 (en) 2017-12-19 2022-08-08 Combined pharmaceutical composition

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
MX2017016719A MX2017016719A (es) 2017-12-19 2017-12-19 Composición farmacéutica combinada para la prevención de la formación de productos finales de la glicación avanzada.

Publications (1)

Publication Number Publication Date
MX2017016719A true MX2017016719A (es) 2020-01-20

Family

ID=66815452

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017016719A MX2017016719A (es) 2017-12-19 2017-12-19 Composición farmacéutica combinada para la prevención de la formación de productos finales de la glicación avanzada.

Country Status (2)

Country Link
US (2) US11406636B2 (es)
MX (1) MX2017016719A (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020236622A1 (en) * 2019-05-17 2020-11-26 Trustees Of Tufts College Compositions and methods for preventing inflammatory conditions
JP2021023147A (ja) * 2019-07-31 2021-02-22 ハウス食品株式会社 グルコース酸化物生成抑制用組成物、ＡＧＥｓ生成抑制用組成物、及び、ＡＧＥｓを介したタンパク質分子間の架橋の切断用組成物
JP2023554640A (ja) * 2020-12-17 2023-12-28 サミ－サビンサ グループ リミテッド 慢性炎症状態において終末糖化産物受容体（ｒａｇｅ）を標的とするための組成物

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070059378A1 (en) * 2001-02-02 2007-03-15 Metagenics, Inc. Medical composition for balancing bodily processes
TW200613009A (en) * 2004-06-11 2006-05-01 Ono Pharmaceutical Co Capsule having chewing stability
WO2008021210A2 (en) * 2006-08-11 2008-02-21 Combinatorx, Incorporated Methods and compositions for the treatment of neurodegenerative disorders
WO2011121989A1 (ja) * 2010-03-29 2011-10-06 株式会社カネカ 被覆用油脂組成物及びそれを用いた粒子状組成物
US9271953B2 (en) * 2013-03-13 2016-03-01 Genetic Disease Investigators, LLC Methods for correction of organ dysfunction
WO2016179097A1 (en) 2015-05-04 2016-11-10 Stella Maris Methods for treating mitochondrial damage diseases

Also Published As

Publication number Publication date
US20190183892A1 (en) 2019-06-20
US11406636B2 (en) 2022-08-09
US20220370449A1 (en) 2022-11-24

Similar Documents

Publication Publication Date Title
MX2017016719A (es) Composición farmacéutica combinada para la prevención de la formación de productos finales de la glicación avanzada.
CO6210803A2 (es) Formulaciones liquidas formadoras de pelicula dermica para la liberacion de farmaco a la piel
JP2019517542A5 (es)
RU2017119230A (ru) Лечение пигментной дистрофии сетчатки n-ацетилцистеинамидом
WO2011159100A3 (ko) 항암 활성을 나타내는 약제학적 조성물
MX2018000084A (es) Una composicion farmaceutica que comprende amlodipino, valsartan y rosuvastatina.
IL254641B2 (en) Methods and preparations including naproxen and fexofenamide for relieving symptoms of dizziness associated with alcohol consumption
JP2010540566A5 (es)
JP2011513340A5 (es)
Roopashri et al. Radiotherapy and chemotherapy induced oral mucositis--prevention and current therapeutic modalities
WO2012042197A3 (en) Low dose pharmaceutical composition comprising zanamivir
MX2019014687A (es) Formulaciones farmaceuticas orales de remogliflozina.
WO2007144081A3 (de) Raucherentwöhnungs-kombinationswafer
Morazzoni et al. SAMITAL®: a new botanical drug for the treatment of mucositis induced by oncological therapies
MX2015013330A (es) Composicion farmaceutica combinada para la prevencion de las complicaciones de la diabetes mellitus.
US20210401915A1 (en) Compositions and methods for the management of mucositis in mammals
US20220323535A1 (en) Health supplement
MX2023005763A (es) Composiciones y metodos para la administracion dermica profunda de farmacos.
JP2014129321A5 (es)
WO2011108882A3 (ko) 유효성분으로서 레바미피드를 함유하는 골관절염 예방 또는 치료용 약학 조성물
Singla et al. (429) Randomized, double-blind, placebo-controlled, phase 3 study of the safety and analgesic efficacy of MNK-155 extended-release hydrocodone bitartrate/acetaminophen tablets (HB/APAP ER) in an acute pain model
Cheruvu et al. (428) Single-and multiple-dose pharmacokinetics of extended-release hydrocodone bitartrate/acetaminophen tablets (MNK-155) with a loading dose of 3 tablets followed by 2 tablets administered q12h compared with immediate-release hydrocodone bitartrate and acetaminophen tablets
JP6698034B2 (ja) 冷え症等の全身症状改善用経口組成物
RU2739187C2 (ru) Комплексное средство для облегчения похмельного синдрома и гепатопротекторного действия
RU2580290C2 (ru) Фармацевтическая композиция лекарственного средства седативного и спазмолитического действия в форме мягких желатиновых капсул (варианты)

Legal Events

Date Code Title Description
GB Transfer or rights

Owner name: GIDD COMMERCIAL USA, INC.